Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-753 in Relapsed/Refractory B-Cell ALL
NCT07674823Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KITE-753 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events and Recommended Phase 2 Dose. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
KITE-753
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07674823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674823.